Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urokinase does not upregulate the vascular endothelial cell-mediated inflammatory response

J M Rhodes1, A F Tilberg, R R Gifford

  • 1Department of Surgery, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center 17033, USA.

Journal of Vascular Surgery
|March 1, 1997
PubMed
Summary

Urokinase, used for clot breakdown, does not harm vascular endothelial cells or increase inflammation at clinical doses. This suggests it won't trigger vascular inflammation in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspective: Vitamin D deficiency and COVID-19 severity - plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis.

Journal of internal medicine·2020
Same author

Food additives: Assessing the impact of exposure to permitted emulsifiers on bowel and metabolic health - introducing the FADiets study.

Nutrition bulletin·2019
Same author

A drunk and disorderly country: a nationwide cross-sectional survey of alcohol use and misuse in Great Britain.

Frontline gastroenterology·2017
Same author

Dietary exposure to emulsifiers and detergents and the prevalence of cardiovascular disease.

QJM : monthly journal of the Association of Physicians·2017
Same author

MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.

Cell death & disease·2014
Same author

Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis.

British journal of cancer·2014

Area of Science:

  • Vascular Biology
  • Cellular Immunology
  • Pharmacology

Background:

  • Urokinase is a thrombolytic agent with established clinical use.
  • Its direct impact on vascular endothelial cells remains largely uncharacterized.
  • Understanding these effects is crucial for assessing potential inflammatory responses during treatment.

Purpose of the Study:

  • To investigate the in vitro effects of urokinase on human umbilical vein endothelial cells (HUVEC).
  • To assess urokinase's impact on HUVEC viability, growth, and adhesion molecule expression.
  • To determine urokinase's influence on the interaction between HUVECs and leukocytes or platelets.

Main Methods:

  • HUVECs were cultured with varying urokinase concentrations (0–10,000 IU/ml).
  • Cell viability was assessed over 1–4 days.

Related Experiment Videos

  • Adhesion of labeled leukocytes and platelets to HUVECs was quantified after 4–72 hours of urokinase exposure.
  • Expression of key adhesion molecules (ICAM-1, VCAM-1, ELAM-1) was measured via flow cytometry.

    • Main Results:

    • Suprapharmacologic urokinase concentrations (>2000 IU/ml) reduced HUVEC viability.
    • Clinically relevant urokinase concentrations (≤500 IU/ml) did not affect HUVEC viability or growth.
    • No significant increase in leukocyte or platelet adhesion to HUVECs was observed.
    • Urokinase did not upregulate the expression of tested adhesion molecules.

    Conclusions:

    • Urokinase at clinically relevant doses is safe for vascular endothelial cells in vitro.
    • It does not induce cellular changes associated with the vascular inflammatory response.
    • These findings imply that therapeutic use of urokinase is unlikely to initiate an in vivo vascular inflammatory response.